|
[1]
|
Shi, J., Cheng, J., Liu, S., Zhu, Y. and Zhu, M. (2024) Acinetobacter Baumannii: An Evolving and Cunning Opponent. Frontiers in Microbiology, 15, Article 1332108. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Dubey, V., Reza, N. and Hope, W. (2025) Drug-Resistant Acinetobacter baumannii: Mortality, Emerging Treatments, and Future Pharmacological Targets for a WHO Priority Pathogen. Clinical Microbiology Reviews, 38, e00279-24. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Naseef Pathoor, N., Valsa, V., Ganesh, P.S. and Gopal, R.K. (2025) From Resistance to Treatment: The Ongoing Struggle with Acinetobacter baumannii. Critical Reviews in Microbiology, 51, 1270-1291. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Li, S., Jiang, G., Wang, S., Wang, M., Wu, Y., Zhang, J., et al. (2025) Emergence and Global Spread of a Dominant Multidrug-Resistant Clade within Acinetobacter baumannii. Nature Communications, 16, Article No. 2787. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Marino, A., Augello, E., Stracquadanio, S., Bellanca, C.M., Cosentino, F., Spampinato, S., et al. (2024) Unveiling the Secrets of Acinetobacter Baumannii: Resistance, Current Treatments, and Future Innovations. International Journal of Molecular Sciences, 25, Article 6814. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Shein, A.M.S., Hongsing, P., Smith, O.K., Phattharapornjaroen, P., Miyanaga, K., Cui, L., et al. (2024) Current and Novel Therapies for Management of Acinetobacter baumannii-Associated Pneumonia. Critical Reviews in Microbiology, 51, 441-462. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
王月涵, 王雨婷, 李泽东, 等. 鲍曼不动杆菌耐药和毒力机制与CRISPR/Cas系统的抑制作用[J]. 中国新药与临床杂志, 2025, 44(12): 893-898.
|
|
[8]
|
蔡果果, 王春艳. 耐碳青霉烯类鲍曼不动杆菌耐药机制及治疗研究进展[J]. 现代医药卫生, 2019, 35(2): 234-237.
|
|
[9]
|
Hamidian, M. and Nigro, S.J. (2019) Emergence, Molecular Mechanisms and Global Spread of Carbapenem-Resistant Acinetobacter baumannii. Microbial Genomics, 5, e000306.
|
|
[10]
|
毛璞, 李建春, 邱桂霞, 等. 重症监护病房耐碳青霉烯类抗生素鲍曼不动杆菌耐药机制研究[J]. 中国感染与化疗杂志, 2015, 15(3): 253-256.
|
|
[11]
|
Adeyemi, F.M., Akinlade, E.A., Yusuf-Omoloye, N.A., Ajigbewu, O.H., Dare, A.P., Wahab, A.A., et al. (2025) Carbapenem-Resistance in Acinetobacter baumannii: Prevalence, Antibiotic Resistance Profile and Carbapenemase Genes in Clinical and Hospital Environmental Strains. BMC Infectious Diseases, 25, Article No. 786. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
张杰, 张伟鹏. 鲍曼不动杆菌耐药机制及其研究方法[J]. 中国抗生素杂志, 2026, 51(2): 171-183.
|
|
[13]
|
Lee, C.R., Lee, J.H., Park, M., Park, K.S., Bae, I.K., Kim, Y.B., et al. (2017) Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment Options. Frontiers in Cellular and Infection Microbiology, 7, Article 55. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Holt, K., Kenyon, J.J., Hamidian, M., Schultz, M.B., Pickard, D.J., Dougan, G., et al. (2016) Five Decades of Genome Evolution in the Globally Distributed, Extensively Antibiotic-Resistant Acinetobacter baumannii Global Clone 1. Microbial Genomics, 2, 1-16. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Jaimes, F.E., Hondros, A.D., Kinkead, J., Milton, M.E., Thompson, R.J., Figg, A.M., et al. (2025) PmrA Mutations in Drug-Resistant Acinetobacter baumannii Affect Sensor Kinase-Response Regulator Interaction and Phosphotransfer. Microorganisms, 13, Article 2600. [Google Scholar] [CrossRef]
|
|
[16]
|
Wang, H., Ishchenko, A., Skudlarek, J., Shen, P., Dzhekieva, L., Painter, R.E., et al. (2024) Cerastecins Inhibit Membrane Lipooligosaccharide Transport in Drug-Resistant Acinetobacter baumannii. Nature Microbiology, 9, 1244-1255. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
佘婷婷, 沈继录, 徐元宏, 等. 广泛耐药鲍曼不动杆菌耐碳青霉烯类抗生素膜蛋白机制研究[J]. 中国感染与化疗杂志, 2012, 12(4): 280-284.
|
|
[18]
|
Scribano, D., Cheri, E., Pompilio, A., Di Bonaventura, G., Belli, M., Cristina, M., et al. (2024) Acinetobacter baumannii OmpA-Like Porins: Functional Characterization of Bacterial Physiology, Antibiotic-Resistance, and Virulence. Communications Biology, 7, Article No. 948. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
王健楠, 杨毅. 碳青霉烯类耐药鲍曼不动杆菌的流行与播散规律研究进展[J]. 医药前沿, 2025, 15(36): 45-49.
|
|
[20]
|
Zack, K.M., Sorenson, T. and Joshi, S.G. (2024) Types and Mechanisms of Efflux Pump Systems and the Potential of Efflux Pump Inhibitors in the Restoration of Antimicrobial Susceptibility, with a Special Reference to Acinetobacter baumannii. Pathogens, 13, Article 197. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Liu, C., Liu, J., Lu, Q., Wang, P. and Zou, Q. (2024) The Mechanism of Tigecycline Resistance in Acinetobacter baumannii under Sub-Minimal Inhibitory Concentrations of Tigecycline. International Journal of Molecular Sciences, 25, Article 1819. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Xie, L., Li, J., Peng, Q., Liu, X., Lin, F., Dai, X., et al. (2025) Contribution of RND Superfamily Multidrug Efflux Pumps AdeABC, AdeFGH, and AdeIJK to Antimicrobial Resistance and Virulence Factors in Multidrug-Resistant Acinetobacter baumannii Aye. Antimicrobial Agents and Chemotherapy, 2024, e01858-24. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
蔺飞, 杜冰洁, 高灿, 等. 鲍曼不动杆菌生物被膜对抗菌药物耐药性的影响[J]. 中国感染控制杂志, 2018, 17(1): 1-5.
|
|
[24]
|
江培涛, 方敏, 刘棵文, 等. 生物膜抑制剂对泛耐药鲍曼不动杆菌碳青霉烯类耐药性的影响[J]. 中国抗生素杂志, 2018, 43(10): 1291-1295.
|
|
[25]
|
Javadi, K., Ghaemian, P., Baziboron, M. and Pournajaf, A. (2025) Investigating the Link between Biofilm Formation and Antibiotic Resistance in Clinical Isolates of Acinetobacter baumannii. International Journal of Microbiology, 2025, Article 1009049. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Ababneh, Q., Aldaken, N., Jaradat, Z., Al-Rousan, E., Inaya, Z., Alsaleh, D., et al. (2025) Predominance of Extensively-Drug Resistant Acinetobacter baumannii Carrying Bla OXA-23 in Jordanian Patients Admitted to the Intensive Care Units. PLOS ONE, 20, e0317798. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Scoffone, V.C., Trespidi, G., Barbieri, G., Arshad, A., Israyilova, A. and Buroni, S. (2025) The Evolution of Antimicrobial Resistance in Acinetobacter baumannii and New Strategies to Fight It. Antibiotics, 14, Article 85. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Hamidian, M. and Hall, R.M. (2018) The Abar Antibiotic Resistance Islands Found in Acinetobacter Baumannii Global Clone 1—Structure, Origin and Evolution. Drug Resistance Updates, 41, 26-39. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Correa, A., Shehreen, S., Machado, L.C., Thesier, J., Cunic, L.M., Petassi, M.T., et al. (2024) Novel Mechanisms of Diversity Generation in Acinetobacter baumannii Resistance Islands Driven by Tn7-Like Elements. Nucleic Acids Research, 52, 3180-3198. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Oke, M.T., Martz, K., Mocăniță, M., Knezevic, S. and D’Costa, V.M. (2024) Analysis of Acinetobacter P-Type Type IV Secretion System-Encoding Plasmid Diversity Uncovers Extensive Secretion System Conservation and Diverse Antibiotic Resistance Determinants. Antimicrobial Agents and Chemotherapy, 68, e01038-24. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Jiang, X., Shan, X., Yang, X., Zhang, X., Xiang, Y., Chen, Y., et al. (2026) Regulation of Drug Resistance and Virulence of Acinetobacter baumannii by Quorum Sensing System under Antibiotic Pressure. Frontiers in Microbiology, 17, Article 1744356. [Google Scholar] [CrossRef]
|
|
[32]
|
Zhang, R., Li, D., Fang, H., Xie, Q., Tang, H. and Chen, L. (2025) Iron-Dependent Mechanisms in Acinetobacter baumannii: Pathogenicity and Resistance. JAC-Antimicrobial Resistance, 7, dlaf039. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
钟子锐, 周凯楠, 王瑞琦, 等. 新型铁载体抗菌药物头孢地尔耐药研究进展[J]. 中国感染与化疗杂志, 2024, 24(6): 731-735.
|
|
[34]
|
Kabbara, W.K., Sadek, E. and Mansour, H. (2025) Sulbactam-Durlobactam: A Novel Antibiotic Combination for the Treatment of Acinetobacter baumannii-Calcoaceticus Complex (ABC) Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia. Canadian Journal of Infectious Diseases and Medical Microbiology, 2025, Article 2001136. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Burgos, R.M., Wang, Y., Hou, J. and Danziger, L.H. (2025) Pharmacokinetic Drug Evaluation of Co-Packaged Sulbactam for Injection and Durlobactam for Injection for the Treatment of Acinetobacter baumannii-Calcoaceticus Complex in HABP/VABP. Expert Opinion on Drug Metabolism & Toxicology, 21, 1135-1149. [Google Scholar] [CrossRef]
|
|
[36]
|
Arshad, N., Azzam, W., Zilberberg, M.D. and Shorr, A.F. (2025) Acinetobacter Baumannii Complex Infections: New Treatment Options in the Antibiotic Pipeline. Microorganisms, 13, Article 356. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Halim, J., Bouzo, J. and Carabetta, V.J. (2025) Evaluation of Sulbactam/Durlobactam Activity and Synergy against Highly Drug-Resistant Acinetobacter baumannii Strains. JAC-Antimicrobial Resistance, 7, dlaf220. [Google Scholar] [CrossRef]
|
|
[38]
|
Eslami, M., Safaripour, A., Banihashemian, S.Z., Nikjoo Niaragh, S., Hemmati, M.A., Shojaeian, A., et al. (2025) Innovative Antibiotic Therapies for Carbapenem-Resistant Gram-Negative Bacterial Infections: Clinical Efficacy, Safety, and Comparative Studies. Microorganisms, 13, Article 295. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Russo, A. and Serapide, F. (2025) The Multifaceted Landscape of Healthcare-Associated Infections Caused by Carbapenem-Resistant Acinetobacter baumannii. Microorganisms, 13, Article 829. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Zhang, S., Di, L., Qi, Y., Qian, X. and Wang, S. (2024) Treatment of Infections Caused by Carbapenem-Resistant Acinetobacter baumannii. Frontiers in Cellular and Infection Microbiology, 14, Article 1395260. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Karampatakis, T., Tsergouli, K. and Behzadi, P. (2025) Carbapenem-Resistant Acinetobacter baumannii: Virulence Factors, Molecular Epidemiology, and Latest Updates in Treatment Options. Microorganisms, 13, Article 1983. [Google Scholar] [CrossRef]
|
|
[42]
|
高金丹, 方强, 苏群. 替加环素治疗多重或泛耐药鲍曼不动杆菌引起的重症肺炎的疗效评价[J]. 中国抗生素杂志, 2015, 40(8): 621-625.
|
|
[43]
|
Qian, C., Hu, P., Guo, W., Han, Y., Yu, P., Zhang, Y., et al. (2024) Genome Analysis of Tigecycline-Resistant Acinetobacter baumannii Reveals Nosocomial Lineage Shifts and Novel Resistance Mechanisms. Journal of Antimicrobial Chemotherapy, 79, 2965-2974. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
Papazachariou, A., Tziolos, R., Karakonstantis, S., Ioannou, P., Samonis, G. and Kofteridis, D.P. (2024) Treatment Strategies of Colistin Resistance Acinetobacter baumannii Infections. Antibiotics, 13, Article 423. [Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
Blake, K.S., Xue, Y., Gillespie, V.J., Fishbein, S.R.S., Tolia, N.H., Wencewicz, T.A., et al. (2025) The Tetracycline Resistome Is Shaped by Selection for Specific Resistance Mechanisms by Each Antibiotic Generation. Nature Communications, 16, Article No. 1452. [Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
Song, M.H., Xiang, B.X., Yang, C.Y., et al. (2024) A Pilot Clinical Risk Model to Predict Polymyxin-Induced Nephrotoxicity: A Real-World, Retrospective Cohort Study. Journal of Antimicrobial Chemotherapy, 79, 1919-1928. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Wang, S.W., Shi, Z.Q., Zhu, J.X., et al. (2025) Glutamine Potentiates Cefoperazone-Sulbactam Activity against Acinetobacter baumannii by Increasing Drug Uptake and Ros. ACS Infectious Diseases, 11, 3222-3236. [Google Scholar] [CrossRef]
|
|
[48]
|
Zhao, L., Guo, X., Zhang, Z., Lu, X., Zeng, Q., Fan, T., et al. (2024) Novel Berberine Derivatives as Adjuvants in the Battle against Acinetobacter Baumannii: A Promising Strategy for Combating Multi-Drug Resistance. Chinese Chemical Letters, 35, Article 109506. [Google Scholar] [CrossRef]
|
|
[49]
|
Jiang, P., Luo, X., Zhao, J., Sun, J., Su, Z. and Cheng, P. (2025) Evolutionary Dynamics and Research Hotspots of Phage Applications against Acinetobacter baumannii Infections from the Past to the New Era. Frontiers in Microbiology, 16, Article 1606351. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
Zhi, Y., Yan, D., Tang, Q., Xiao, L., Cai, A., Sun, M., et al. (2025) Identification of Multi-Drug Resistant Acinetobacter baumannii Phage YZ2 and Evaluation of Its Therapeutic Efficacy in Vivo and in Vitro. Frontiers in Microbiology, 16, Article 1657539. [Google Scholar] [CrossRef]
|
|
[51]
|
Sherif, M.M., Abdelaziz, N.A., Alshahrani, M.Y., Saleh, S.E. and Aboshanab, K.M. (2025) In Vitro, Genomic Characterization and Pre-Clinical Evaluation of a New Thermostable Lytic Obolenskvirus Phage Formulated as a Hydrogel against Carbapenem-Resistant Acinetobacter baumannii. Scientific Reports, 15, Article No. 17149. [Google Scholar] [CrossRef] [PubMed]
|
|
[52]
|
高光俊, 徐杰. 噬菌体在感染性疾病治疗中的研究进展[J]. 中国抗生素杂志, 2026, 51(1): 33-40.
|
|
[53]
|
Orozco-Ochoa, A.K., González-Gómez, J.P., Quiñones, B., Castro-del Campo, N., Valdez-Torres, J.B. and Chaidez-Quiroz, C. (2025) Bacteriophage Indie Resensitizes Multidrug-Resistant Acinetobacter baumannii to Antibiotics in Vitro. Scientific Reports, 15, Article No. 11578. [Google Scholar] [CrossRef] [PubMed]
|
|
[54]
|
Liu, Z., Tan, X., Xiong, M., Lu, S., Yang, Y., Zhu, H., et al. (2025) Efficacy of Precisely Tailored Phage Cocktails Targeting Carbapenem-Resistant Acinetobacter baumannii Reveals Evolutionary Trade-Offs: A Proof-of-Concept Study. eBioMedicine, 120, Article 105942. [Google Scholar] [CrossRef]
|
|
[55]
|
Tarasenko, A., Papudeshi, B.N., Grigson, S.R., Mallawaarachchi, V., Hutton, A.L.K., Warner, M.S., et al. (2025) Reprogramming Resistance: Phage-Antibiotic Synergy Targets Efflux Systems in ESKAPEE Pathogens. mBio, 16, e01822-25. [Google Scholar] [CrossRef]
|
|
[56]
|
Citorik, R.J., Mimee, M. and Lu, T.K. (2014) Sequence-Specific Antimicrobials Using Efficiently Delivered RNA-Guided Nucleases. Nature Biotechnology, 32, 1141-1145. [Google Scholar] [CrossRef] [PubMed]
|
|
[57]
|
Bikard, D., Euler, C.W., Jiang, W., Nussenzweig, P.M., Goldberg, G.W., Duportet, X., et al. (2014) Exploiting Crispr-Cas Nucleases to Produce Sequence-Specific Antimicrobials. Nature Biotechnology, 32, 1146-1150. [Google Scholar] [CrossRef] [PubMed]
|
|
[58]
|
Ma, S., Zhu, F., Zhang, P., Xu, Y., Zhou, Z., Yang, H., et al. (2025) Development of a Novel Multi-Epitope Subunit mRNA Vaccine Candidate to Combat Acinetobacter baumannii. Scientific Reports, 15, Article No. 1410. [Google Scholar] [CrossRef] [PubMed]
|
|
[59]
|
Beig, M., Sholeh, M., Moradkasani, S., Shahbazi, B. and Badmasti, F. (2025) Development of a Multi-Epitope Vaccine against Acinetobacter baumannii: A Comprehensive Approach to Combating Antimicrobial Resistance. PLOS ONE, 20, e0319191. [Google Scholar] [CrossRef] [PubMed]
|
|
[60]
|
Heidarinia, H., Tajbakhsh, E., Bahrami, Y. and Rostamian, M. (2025) Design a Multi-Epitope Vaccine Candidate against Acinetobacter baumannii Using Advanced Computational Methods. AMB Express, 15, Article No. 103. [Google Scholar] [CrossRef] [PubMed]
|
|
[61]
|
Higham, S.L., Wang, Z., Murugaiah, V., Song, J., Thomas, C., Zhang, H., et al. (2025) Intranasal Delivery of mRNA Expressing Newly Identified Acinetobacter baumannii Antigens Protects against Bacterial Lung Disease. npj Vaccines, 10, Article No. 144. [Google Scholar] [CrossRef] [PubMed]
|
|
[62]
|
Saperi, A.A., Hazan, A., Zulkifli, N., Lee, H., MatRahim, N. and AbuBakar, S. (2025) Immunization with Inactivated Bacillus Subtilis Spores Expressing TonB-Dependent Receptor (TBDR) Protects against Multidrug-Resistant Acinetobacter baumannii Infection. Vaccines, 13, Article 616. [Google Scholar] [CrossRef] [PubMed]
|
|
[63]
|
Guo, T., Yang, J., Zhou, N., Sun, X., Huan, C., Lin, T., et al. (2025) Cas3 of Type I-Fa CRISPR-Cas System Upregulates Bacterial Biofilm Formation and Virulence in Acinetobacter baumannii. Communications Biology, 8, Article No. 750. [Google Scholar] [CrossRef] [PubMed]
|
|
[64]
|
Yosboonruang, A., Kiddee, A., Siriphap, A., Pook-In, G., Suwancharoen, C., Duangjai, A., et al. (2025) Potential of Cannabidiol (CBD) to Overcome Extensively Drug-Resistant Acinetobacter baumannii. BMC Complementary Medicine and Therapies, 25, Article No. 308. [Google Scholar] [CrossRef] [PubMed]
|
|
[65]
|
Gutierrez-Montiel, D., Guerrero-Barrera, A.L., Ramírez-Castillo, F.Y., Galindo-Guerrero, F., Ornelas-García, I.G., Chávez-Vela, N.A., et al. (2024) Guava Leaf Extract Exhibits Antimicrobial Activity in Extensively Drug-Resistant (XDR) Acinetobacter baumannii. Molecules, 30, Article 70. [Google Scholar] [CrossRef] [PubMed]
|
|
[66]
|
Abdulkareem, A.H., Mukhles Ahmed, M., Abed Latef Al-Meani, S. and Abdulkareem, E.H. (2025) Integrated in Silico-in Vitro and Pharmacokinetic Profiling of Thymus Vulgaris-Derived Metabolites Targeting Multidrug Resistance Pathways in Extensively Drug-Resistant Acinetobacter baumannii (muks92). Frontiers in Microbiology, 16, Article 1680686. [Google Scholar] [CrossRef]
|
|
[67]
|
Hussain, A., Bhando, T., Casius, A., Gupta, R. and Pathania, R. (2025) Deciphering Meropenem Persistence in Acinetobacter baumannii Facilitates Discovery of Anti-Persister Activity of Thymol. Antimicrobial Agents and Chemotherapy, 69, e0138124. [Google Scholar] [CrossRef] [PubMed]
|
|
[68]
|
Javadi, K., Ahmadi, M.H., Rajabnia, M. and Halaji, M. (2026) Enhancing Antibiotic Efficacy with Curcumin: A Novel Approach to Combat Multidrug-Resistant Acinetobacter baumannii. Current Microbiology, 83, Article No. 186. [Google Scholar] [CrossRef]
|